secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161089
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CABA-201 shows no CRS/ICANS/SAEs in first two patients; B cell depletion and disease score improvements observed
--------------------------------------------------------------------------------

- First patient in IMNM cohort had creatinine kinase drop from 617 to 308 and TIS of 30 at week 12.
- First SLE patient had SLEDAI-2K score drop from 26 to 10 at week 4.
- Complete B cell depletion by day 15 post-infusion; immature naïve B cell repopulation seen at week 8 in IMNM patient.
- All chronic maintenance therapies discontinued for both patients except planned prednisone taper for SLE patient.
- 18 sites open, 5 patients enrolled as of June 12, 2024; initial data support current dose of 1e6 cells/kg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524161089/0001193125-24-161089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524161089/d851455d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer